No headlines found.
Business Wire (Tue, 16-Apr 8:00 AM ET)
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
Business Wire (Fri, 12-Apr 8:00 AM ET)
Business Wire (Thu, 11-Apr 8:00 AM ET)
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
Business Wire (Tue, 9-Apr 8:00 AM ET)
Charles River to Perform Plasmid Production for Ship of Theseus
Business Wire (Thu, 4-Apr 8:00 AM ET)
Globe Newswire (Tue, 2-Apr 9:00 PM ET)
Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024
Business Wire (Mon, 1-Apr 8:00 AM ET)
Charles River Laboratories Publishes 2023 Corporate Citizenship Report
Business Wire (Wed, 27-Mar 8:00 AM ET)
Business Wire (Thu, 21-Mar 8:00 AM ET)
Business Wire (Thu, 14-Mar 8:00 AM ET)
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Charles River Laboratories International trades on the NYSE stock market under the symbol CRL.
As of April 19, 2024, CRL stock price climbed to $229.25 with 69,308 million shares trading.
CRL has a beta of 1.59, meaning it tends to be more sensitive to market movements. CRL has a correlation of 0.34 to the broad based SPY ETF.
CRL has a market cap of $11.65 billion. This is considered a Large Cap stock.
Last quarter Charles River Laboratories International reported $1 billion in Revenue and $2.46 earnings per share. This beat revenue expectation by $22 million and exceeded earnings estimates by $.06.
In the last 3 years, CRL stock traded as high as $460.21 and as low as $161.65.
The top ETF exchange traded funds that CRL belongs to (by Net Assets): VTI, VB, VOO, VBK, SPY.
CRL has underperformed the market in the last year with a price return of +11.3% while the SPY ETF gained +21.8%. However, in the short term, CRL had mixed performance relative to the market. It has outperformed in the last 3 months, returning +11.2% vs +4.8% return in SPY. But in the last 2 weeks, CRL shares have been beat by the market, returning -8.5% compared to an SPY return of -2.9%.
CRL support price is $223.15 and resistance is $231.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRL stock will trade within this expected range on the day.